Glucotrack, INC 8-K filings

Glucotrack, Inc. closed a public offering and concurrent private placement, raising approximately $9.1 million and securing shareholder support for key proposals including a reverse stock split.

Glucotrack, Inc. has successfully closed a $10 million public offering and a concurrent private placement converting $4 million in debt, aiming to bolster its working capital and general corporate activities.

Glucotrack, Inc. has announced a public offering of approximately 7.195 million shares of common stock, expected to raise $10 million, along with a concurrent private placement to convert $4 million in debt to equity.

Glucotrack, Inc. will present its continuous blood glucose monitor at the 2024 BioFuture Conference, highlighting its long-term implantable technology.

Glucotrack will present updated preclinical data for its continuous blood glucose monitor at the 2024 Diabetes Technology Meeting.

GlucoTrack, Inc. stockholders approved the issuance of shares related to a note and warrants at a special meeting held on September 24, 2024.

GlucoTrack, Inc. converted approximately $259,300 of debt into common stock and issued warrants to an investor on September 5, 2024.

Glucotrack, Inc. has appointed Paul V. Goode and John Ballantyne to its Board of Directors, effective August 27, 2024, with Mr. Ballantyne's appointment announced in a press release on September 3, 2024.

Glucotrack, Inc. has announced the appointment of Sandie Martha as Vice President of Clinical Operations, bringing extensive experience in clinical trials to the company.

A recent market research study indicates that over 50% of surveyed diabetes patients are open to adopting Glucotrack's new continuous blood glucose monitor concept.

Glucotrack, Inc. will present market research data on their continuous blood glucose monitor concept at the Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference.

Glucotrack, Inc. has secured $4 million in funding through a convertible promissory note and warrants to advance the development of its continuous blood glucose monitor.

Glucotrack, Inc. has entered into a private placement of convertible promissory notes, raising $350,000 from investors.

GlucoTrack Inc. distributed a slide presentation on July 8, 2024, as a shareholder update.

Glucotrack, Inc. has entered into a private placement agreement, raising $100,000 through the issuance of unsecured promissory notes and warrants.

Glucotrack, Inc. has appointed Andy Balo, a seasoned medical technology executive, to its Board of Directors and amended its bylaws to reduce the quorum requirement for shareholder meetings.

Glucotrack's implantable continuous glucose monitor successfully completed a 60-day preclinical study, demonstrating the feasibility of glucose monitoring in the epidural space.

GlucoTrack, Inc. is facing potential delisting from the Nasdaq Stock Market after failing to meet minimum bid price and stockholders' equity requirements, and has requested a hearing to appeal the decision.

GlucoTrack, Inc. has completed a 1-for-5 reverse stock split, reducing its outstanding shares from approximately 27.4 million to 5.5 million, effective May 17, 2024.

Glucotrack's implantable continuous glucose monitor successfully completed the first 30 days of a 60-day preclinical study, demonstrating accurate glucose tracking in the epidural space.

Glucotrack, Inc. has announced a 1-for-5 reverse stock split of its common stock, effective May 20, 2024, to meet Nasdaq's minimum bid price requirement.

GlucoTrack, Inc. held its 2024 Annual Meeting of Stockholders, where key proposals including the approval of a new equity incentive plan, the election of directors, and a reverse stock split were passed.

GlucoTrack, Inc. exchanged common stock purchase warrants for 3,593,203 shares of common stock on February 13, 2024.

GlucoTrack, Inc. has released an investor presentation on its website, which it may use in whole or in part for presentations to investors and analysts.